Paragon Biosciences: Accelerating Life Science Innovation2021-08-17T21:22:47-05:00

ACCELERATING LIFE SCIENCE INNOVATION

Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.

ACCELERATING LIFE SCIENCE INNOVATION

Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.

ACCELERATING LIFE SCIENCE INNOVATION

Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.

“Challenges which others have deemed unsolvable are the problems we are solving.”

~ Jeffrey S. Aronin

Paragon founder, chairman and CEO

Portfolio

Since 2017, Paragon has successfully launched seven portfolio companies, including a recent upsized IPO, while maintaining a consistent flow of companies in development.

Leveraging its proprietary fibroblast technology platform to expand an innovative gene therapy pipeline, developing personalized treatments for underserved disorders, including epidermolysis bullosa and localized scleroderma.

Castle Creek Biosciences

Concentrating on cell therapy treatments for serious diseases with high, unmet needs with an initial focus on the eye, including geographic atrophy age-related macular degeneration and advanced retinitis pigmentosa.

Circ Biosciences

Creating treatments for central nervous system movement disorders and fluency disorders, including  Tourette syndrome and childhood-onset fluency disorder (stuttering) in adults.

Emalex Biosciences

Evozyne is combining the exquisite complexity of nature with advanced machine learning to create novel proteins with extraordinary impact across a variety of industries.

Evozyne

Commercializing biopharmaceutical treatment options for people living with rare diseases, including disorders of sleep and wakefulness, such as narcolepsy, Prader-Willi syndrome and myotonic dystrophy.

Harmony Biosciences

Assisting radiologists to significantly improve clinical assessment and characterization of cancerous breast abnormalities through artificial intelligence-driven technology that enhances clinical insights.

Qlarity Imaging

Developing first in-kind therapies to treat oral premalignant lesions, a high, unmet need, by eliminating lesions before they become malignant.

Skyline Biosciences LLC

News

Go to Top